Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
ImmuCell Corp
ICCC
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$10.45
-0.06
-0.57%
Últ. Act.: Oct 14, 9:15 AM
$11.05
0.54
5.1%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
ImmuCell Financials
ImmuCell (ICCC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ImmuCell Sees Q3 Sales $8.000M
ImmuCell (NASDAQ:ICCC) sees Q3 sales of $8.000 million.
Benzinga Newsdesk
PRO
ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
Benzinga Newsdesk
PRO
ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.20 per share. This is a 233.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $7.186 million in sales
Benzinga Newsdesk
PRO
ImmuCell Q2 Total Product Sales Rises 12%
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
Benzinga Newsdesk
PRO
ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.21 per share. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $10.357 million in sales this
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
